Literature DB >> 24900590

Identification of a Novel and Selective Series of Itk Inhibitors via a Template-Hopping Strategy.

Catherine M Alder1, Martin Ambler1, Amanda J Campbell1, Aurelie C Champigny1, Angela M Deakin1, John D Harling1, Carol A Harris1, Tim Longstaff1, Sean Lynn1, Aoife C Maxwell1, Chris J Mooney1, Callum Scullion1, Onkar M P Singh1, Ian E D Smith1, Donald O Somers1, Christopher J Tame1, Gareth Wayne1, Caroline Wilson1, James M Woolven1.   

Abstract

Inhibition of Itk potentially constitutes a novel, nonsteroidal treatment for asthma and other T-cell mediated diseases. In-house kinase cross-screening resulted in the identification of an aminopyrazole-based series of Itk inhibitors. Initial work on this series highlighted selectivity issues with several other kinases, particularly AurA and AurB. A template-hopping strategy was used to identify a series of aminobenzothiazole Itk inhibitors, which utilized an inherently more selective hinge binding motif. Crystallography and modeling were used to rationalize the observed selectivity. Initial exploration of the SAR around this series identified potent Itk inhibitors in both enzyme and cellular assays.

Entities:  

Keywords:  Interleukin-2 inducible tyrosine kinase; Itk; aminobenzothiazole; kinase inhibitors; kinase selectivity; template hopping

Year:  2013        PMID: 24900590      PMCID: PMC4027447          DOI: 10.1021/ml400206q

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  18 in total

1.  Ligand efficiency: a useful metric for lead selection.

Authors:  Andrew L Hopkins; Colin R Groom; Alexander Alex
Journal:  Drug Discov Today       Date:  2004-05-15       Impact factor: 7.851

Review 2.  Regulation of T-cell responses and disease by tec kinase Itk.

Authors:  Avery August; Melanie J Ragin
Journal:  Int Rev Immunol       Date:  2012-04       Impact factor: 5.311

Review 3.  Fragment-based approaches in drug discovery and chemical biology.

Authors:  Duncan E Scott; Anthony G Coyne; Sean A Hudson; Chris Abell
Journal:  Biochemistry       Date:  2012-06-14       Impact factor: 3.162

4.  Selectivity of kinase inhibitor fragments.

Authors:  Paul Bamborough; Murray J Brown; John A Christopher; Chun-wa Chung; Geoff W Mellor
Journal:  J Med Chem       Date:  2011-06-23       Impact factor: 7.446

5.  Data normalization before statistical analysis: keeping the horse before the cart.

Authors:  A A Hancock; E N Bush; D Stanisic; J J Kyncl; C T Lin
Journal:  Trends Pharmacol Sci       Date:  1988-01       Impact factor: 14.819

Review 6.  Targeting aurora kinases in cancer treatment.

Authors:  Kevin R Kelly; Jeffrey Ecsedy; Devalingam Mahalingam; Steffan T Nawrocki; Swaminathan Padmanabhan; Francis J Giles; Jennifer S Carew
Journal:  Curr Drug Targets       Date:  2011-12       Impact factor: 3.465

7.  Discovery and structure-activity relationship of 3-aminopyrid-2-ones as potent and selective interleukin-2 inducible T-cell kinase (Itk) inhibitors.

Authors:  Jean-Damien Charrier; Andrew Miller; David P Kay; Guy Brenchley; Heather C Twin; Philip N Collier; Sharn Ramaya; Shazia B Keily; Steven J Durrant; Ronald M A Knegtel; Adam J Tanner; Kieron Brown; Adam P Curnock; Juan-Miguel Jimenez
Journal:  J Med Chem       Date:  2011-03-10       Impact factor: 7.446

8.  Covalent inhibitors of interleukin-2 inducible T cell kinase (itk) with nanomolar potency in a whole-blood assay.

Authors:  Christoph W Zapf; Brian S Gerstenberger; Li Xing; David C Limburg; David R Anderson; Nicole Caspers; Seungil Han; Ann Aulabaugh; Ravi Kurumbail; Subarna Shakya; Xin Li; Vikki Spaulding; Robert M Czerwinski; Nilufer Seth; Quintus G Medley
Journal:  J Med Chem       Date:  2012-11-12       Impact factor: 7.446

9.  Structure-based drug design of novel Aurora kinase A inhibitors: structural basis for potency and specificity.

Authors:  Mohane Selvaraj Coumar; Jiun-Shyang Leou; Paritosh Shukla; Jian-Sung Wu; Ajay Kumar Dixit; Wen-Hsing Lin; Chun-Yu Chang; Tzu-Wen Lien; Uan-Kang Tan; Chun-Hwa Chen; John T-A Hsu; Yu-Sheng Chao; Su-Ying Wu; Hsing-Pang Hsieh
Journal:  J Med Chem       Date:  2009-02-26       Impact factor: 7.446

10.  5-Aminomethylbenzimidazoles as potent ITK antagonists.

Authors:  Doris Riether; Renée Zindell; Jennifer A Kowalski; Brian N Cook; Jörg Bentzien; Stéphane De Lombaert; David Thomson; Stanley Z Kugler; Donna Skow; Leslie S Martin; Ernest L Raymond; Hnin Hnin Khine; Kathy O'Shea; Joseph R Woska; Deborah Jeanfavre; Rosemarie Sellati; Kerry L M Ralph; Jennifer Ahlberg; Gabriel Labissiere; Mohammed A Kashem; Steven S Pullen; Hidenori Takahashi
Journal:  Bioorg Med Chem Lett       Date:  2009-02-08       Impact factor: 2.823

View more
  5 in total

1.  Targeting interleukin-2-inducible T-cell kinase (ITK) and resting lymphocyte kinase (RLK) using a novel covalent inhibitor PRN694.

Authors:  Yiming Zhong; Shuai Dong; Ethan Strattan; Li Ren; Jonathan P Butchar; Kelsey Thornton; Anjali Mishra; Pierluigi Porcu; J Michael Bradshaw; Angelina Bisconte; Timothy D Owens; Erik Verner; Ken A Brameld; Jens Oliver Funk; Ronald J Hill; Amy J Johnson; Jason A Dubovsky
Journal:  J Biol Chem       Date:  2015-01-15       Impact factor: 5.157

2.  Synthesis of aminopyrazole analogs and their evaluation as CDK inhibitors for cancer therapy.

Authors:  Sandeep Rana; Yogesh A Sonawane; Margaret A Taylor; Smitha Kizhake; Muhammad Zahid; Amarnath Natarajan
Journal:  Bioorg Med Chem Lett       Date:  2018-10-15       Impact factor: 2.823

3.  Discovery of novel irreversible inhibitors of interleukin (IL)-2-inducible tyrosine kinase (Itk) by targeting cysteine 442 in the ATP pocket.

Authors:  John D Harling; Angela M Deakin; Sébastien Campos; Rachel Grimley; Laiq Chaudry; Catherine Nye; Oxana Polyakova; Christina M Bessant; Nick Barton; Don Somers; John Barrett; Rebecca H Graves; Laura Hanns; William J Kerr; Roberto Solari
Journal:  J Biol Chem       Date:  2013-08-09       Impact factor: 5.157

4.  Targeting SLP76:ITK interaction separates GVHD from GVL in allo-HSCT.

Authors:  Mahinbanu Mammadli; Weishan Huang; Rebecca Harris; Hui Xiong; Samuel Weeks; Adriana May; Teresa Gentile; Jessica Henty-Ridilla; Adam T Waickman; Avery August; Alaji Bah; Mobin Karimi
Journal:  iScience       Date:  2021-03-11

5.  Identification of inactive conformation-selective interleukin-2-inducible T-cell kinase (ITK) inhibitors based on second-harmonic generation.

Authors:  Yoshiji Hantani; Kiyosei Iio; Rie Hantani; Kayo Umetani; Toshihiro Sato; Tracy Young; Katelyn Connell; Sam Kintz; Joshua Salafsky
Journal:  FEBS Open Bio       Date:  2018-07-30       Impact factor: 2.693

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.